Cartesian Therapeutics, Inc.
RNAC
$6.65
-$0.06-0.89%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.80% | -99.11% | -81.16% | -109.18% | -94.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.80% | -99.11% | -81.16% | -109.18% | -94.09% |
| Cost of Revenue | 20.72% | 133.25% | 79.07% | -30.43% | -18.47% |
| Gross Profit | -20.86% | -104.63% | -103.41% | -51.08% | -58.33% |
| SG&A Expenses | 17.59% | 3.03% | -6.05% | -56.62% | -0.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.80% | 12.30% | 25.02% | -43.56% | -8.43% |
| Operating Income | -19.86% | -258.54% | -74.44% | 21.26% | -34.52% |
| Income Before Tax | -48.46% | 14.82% | 68.83% | 94.93% | -168.64% |
| Income Tax Expenses | -- | -- | -- | 101.51% | -- |
| Earnings from Continuing Operations | -48.46% | 14.82% | 68.83% | 94.23% | -168.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.46% | 14.82% | 68.83% | 94.23% | -168.64% |
| EBIT | -19.86% | -258.54% | -74.44% | 21.26% | -34.52% |
| EBITDA | -18.34% | -252.10% | -67.67% | 22.39% | -34.27% |
| EPS Basic | -22.59% | -11.36% | 94.01% | 99.01% | 35.44% |
| Normalized Basic EPS | -72.73% | -210.22% | 77.43% | 97.82% | 75.75% |
| EPS Diluted | -22.59% | -7.41% | 94.01% | 98.98% | 35.44% |
| Normalized Diluted EPS | -72.73% | -215.22% | 77.43% | 97.82% | 75.75% |
| Average Basic Shares Outstanding | 21.10% | 55.35% | 378.45% | 380.19% | 316.10% |
| Average Diluted Shares Outstanding | 21.10% | 48.65% | 378.45% | 380.19% | 316.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |